ストックスクリーナーアプリを入手
7.31
0.41%
0.05
前日終値:
$7.36
開ける：
$7.33
24時間の取引高:
14,656
Relative Volume:
0.08
時価総額：
$6.77M
収益：
-
当期純損益:
$-14.93M
株価収益率:
-0.0275
EPS:
-266.137
ネットキャッシュフロー:
$-15.87M
1週間 パフォーマンス:
+8.20%
1か月 パフォーマンス:
-14.17%
6か月 パフォーマンス:
-8.20%
1年 パフォーマンス:
-92.69%
1日の値動き範囲:
$7.2602
$7.50
1週間の範囲:
$6.50
$8.20
52週間の値動き範囲:
$6.0829
$468.44
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
RNAZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
7.38 | 6.75M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.17 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.91 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
812.47 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.30 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Transcode Therapeutics Inc (RNAZ) 最新ニュース
(RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
TransCode Therapeutics Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma Treatment - citybuzz -
TransCode’s glioblastoma therapy shows promise in preclinical study By Investing.com - Investing.com South Africa
Transcode Therapeutics Ttx-Mc138 phase 2a clinical trial expected in first half of 2026 - marketscreener.com
Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026 - TradingView — Track All Markets
TransCode Therapeutics reports promising preclinical glioblastoma results - TipRanks
TransCode Therapeutics stock soars after promising glioblastoma study By Investing.com - Investing.com Canada
TransCode Therapeutics Publishes Preclinical Data on TTX-MC138 for Glioblastoma - TradingView — Track All Markets
Experimental RNA therapy extends survival in brain cancer animal tests - Stock Titan
Precision Trading with Transcode Therapeutics Inc. (RNAZ) Risk Zones - Stock Traders Daily
TransCode Therapeutics appoints Jack E. Stover to board of directors By Investing.com - Investing.com Nigeria
TransCode Therapeutics Appoints Industry Veteran Jack E. Stover to Board of Directors - citybuzz -
TransCode Therapeutics Strengthens Board with Veteran Financial Expert - TipRanks
Transcode Therapeutics Appoints Jack Stover to Board of Directors - TradingView — Track All Markets
TransCode Therapeutics appoints Jack E. Stover to board of directors - Investing.com India
TransCode Therapeutics expands leadership with appointment of Jack E. Stover to board of directors - marketscreener.com
Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors - TradingView — Track All Markets
Life sciences leader behind a $900M pharma sale joins cancer firm - Stock Titan
Why TransCode Therapeutics Inc. stock is favored by top institutionsQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
TransCode Therapeutics Earnings Notes - Trefis
Is TransCode Therapeutics Inc. stock in correction or buying zoneJuly 2025 Sector Moves & Free Risk Controlled Daily Trade Plans - DonanımHaber
How TransCode Therapeutics Inc. stock benefits from tech adoptionMarket Volume Summary & Daily Profit Maximizing Trade Tips - Улправда
TransCode Therapeutics (NASDAQ:RNAZ) Shares Down 4.6% – Here’s What Happened - Defense World
MSN Money - MSN
TransCode Therapeutics Inc Stock Analysis and ForecastMACD Histogram Signals & Superior Trading Ideas - earlytimes.in
TransCode and Quantum Leap to test cancer therapy in phase 2a trial - Investing.com Australia
TransCode Therapeutics and Quantum Leap Collaborate on Colorectal Cancer Trial Targeting Metastatic Disease - citybuzz
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
TransCode and Quantum Leap to test cancer therapy in phase 2a trial By Investing.com - Investing.com South Africa
TransCode Therapeutics and Quantum Leap Healthcare Collaborative launch a phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's phase 1 trial - marketscreener.com
TransCode Therapeutics Announces Phase 2a Trial Collaboration - TradingView — Track All Markets
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PR Newswire
Buyout Rumor: Why hedge funds are buying NETSTREIT Corp. stockInsider Selling & Expert Curated Trade Ideas - moha.gov.vn
Critical Comparison: TransCode Therapeutics (NASDAQ:RNAZ) & ReNeuron Group (OTCMKTS:RNUGF) - Defense World
Will TransCode Therapeutics Inc. stock see PE expansion2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Is TransCode Therapeutics Inc. stock supported by strong cash flows2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - MSN
Is TransCode Therapeutics Inc. stock a contrarian buyRecession Risk & Technical Pattern Recognition Alerts - newser.com
TransCode Therapeutics, Inc. (RNAZ) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Real time breakdown of TransCode Therapeutics Inc. stock performanceEarnings Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Dividend Review & Accurate Buy Signal Alerts - newser.com
Can TransCode Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Is TransCode Therapeutics Inc. stock resilient to inflationMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
TransCode Therapeutics Inc. recovery potential after sell offQuarterly Earnings Summary & Long-Term Capital Growth Ideas - newser.com
Will TransCode Therapeutics Inc. stock outperform value stocks2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why retail investors favor TransCode Therapeutics Inc. stockWeekly Market Outlook & Weekly High Return Stock Opportunities - newser.com
Transcode Therapeutics Inc (RNAZ) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):